United States Cellular Corporation (USM - Free Report) reported lackluster second-quarter 2019 financial results, wherein the top and the bottom lines missed the respective Zacks Consensus Estimate.
On a GAAP basis, net income for the June quarter was $31 million or 35 cents per share compared with $49 million or 56 cents per share in the year-ago quarter due to lower operating income. The bottom line missed the Zacks Consensus Estimate by 7 cents.
United States Cellular Corporation Price, Consensus and EPS Surprise
Quarterly total operating revenues remained almost flat year over year at $973 million on higher service revenues. However, the momentum was more than offset by lower revenues from equipment sales. The top line lagged the consensus estimate of $1,002 million.
While revenues from service grew 2.3% year over year to $757 million, the same from equipment sales were down 7.3% to $216 million primarily due to decline in gross additions.
Total operating expenses were up 2.7% year over year to $943 million on account of higher depreciation and amortization charges. Operating income was $30 million compared with $56 million in the prior-year quarter. Adjusted EBITDA grew 3.6% year over year to $257 million.
While total cell sites in service were 6,535 at the end of the reported quarter compared with 6,478 a year ago, company-owned towers were 4,116 compared with 4,105.
As of Jun 30, 2019, postpaid ARPU (average revenue per user) grew to $45.90 from $44.74, postpaid ARPA (average revenue per account) was $119.46 compared with $118.57. Postpaid churn rose to 1.23% from 1.19% reported a year ago. Prepaid ARPU increased to $34.43 from $32.32 and prepaid churn decreased to 4.20% from 4.83%.
Cash Flow & Liquidity
During the first six months of 2019, U.S. Cellular generated $476 million of net cash from operations compared with $365 million in the year-ago period. For the same period, the company’s non-GAAP free cash flow totaled $194 million compared with $192 million in the prior-year period.
As of Jun 30, 2019, the wireless telecommunications service provider had $528 million in cash and equivalents, with $1,596 million of net long-term debt.
U.S. Cellular provided estimates for 2019. The company has lowered its revenue outlook only and currently expects total operating revenues to be $3,900-$4,100 million (down from prior estimated $4,000-$4,200 million) due to lower revenues from equipment sales.
Adjusted EBITDA is projected to be $900-$1,050 million. The company anticipates adjusted OIBDA of $725-$875 million. Capital expenditures are expected to be between $625 million and $725 million.
U.S. Cellular continues to strengthen its customer base while improving churn management. It is progressing with its 5G and network modernization initiatives. The company intends to offer the best wireless experience to customers by providing superior quality network and national coverage.
Further, the company acquired new licenses at millimeter wave auctions, giving it access to high-frequency spectrum required to deliver high speed and low latency capabilities of 5G to customers. Markedly, the millimeter wave provides at least 300 MHz of spectrum in markets that serve 97% of its customer base. U.S. Cellular expects to begin commercial launch of 5G services in 2020.
Zacks Rank & Other Stocks to Consider
U.S. Cellular currently sports a Zacks Rank #1 (Strong Buy). A few other top-ranked stocks in the broader industry are Harmonic Inc. (HLIT - Free Report) , Comtech Telecommunications Corp. (CMTL - Free Report) and Nokia Corp. (NOK - Free Report) . While Harmonic and Comtech sport a Zacks Rank #1, Nokia carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Harmonic surpassed earnings estimates in each of the trailing four quarters, the average surprise being 119.9%.
Comtech surpassed earnings estimates in each of the trailing four quarters, the average surprise being 216.7%.
Nokia surpassed earnings estimates thrice in the trailing four quarters, the average positive surprise being 89.3%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>